Fenimore Asset Management Trust has filed a proxy statement supplement with the SEC, providing shareholders with additional information as it prepares for its upcoming meeting scheduled for November 6, 2026. This filing is crucial as it outlines the election of six Trustees and a proposal to change the FAM Small Cap Fund from a diversified to a non-diversified company.
The update emphasizes the importance of governance and transparency within the investment management sector. By detailing the board's attendance and performance metrics, Fenimore is positioning itself as a leader in accountability, which may influence industry standards.
Background
Fenimore Asset Management Trust, an investment management entity based in Cobleskill, New York, focuses on managing various funds, including the FAM Value Fund, FAM Dividend Focus Fund, and FAM Small Cap Fund. The trust has been active in filing with the SEC, with recent submissions including proxy statements and various fund reports.
What the Filing Says
The proxy statement supplement, filed on October 27, 2026, provides new information beyond what was included in the previous Proxy Statement dated September 23, 2026. It highlights that the Board of Trustees held five meetings during the last fiscal year, and all Trustees attended at least 75% of the meetings, with full attendance reported for all Board and applicable Committee meetings.
Impact
This update may affect shareholders of Fenimore Asset Management Trust, as well as potential investors looking at the governance practices of investment firms. The emphasis on board attendance and performance may prompt other firms in the investment management industry to enhance their governance disclosures.
What's Next
The upcoming shareholder meeting on November 6, 2026, will address the election of Trustees and the proposed change in the FAM Small Cap Fund’s diversification status. Further details may be provided in subsequent filings.
Read Next
JPMorgan Trust I Updates Prospectus for Small Cap Equity Fund
JPMorgan Trust I updates prospectus for U.S. Equity Fund
Alland Leila Files Form 3 as Chief Medical Officer
Opus Genetics COO sells shares to meet tax obligations
Nomura ETF Trust II Files Post-Effective Amendment for ETF
JPMorgan Trust I Files New Prospectus for Mid Cap Equity Fund









